NCT01651468

Brief Summary

Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 27, 2012

Completed
4.1 years until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
3.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

November 28, 2017

Status Verified

February 1, 2017

Enrollment Period

3.3 years

First QC Date

July 25, 2012

Last Update Submit

November 26, 2017

Conditions

Von Willebrand DiseaseMenorrhagia

Keywords

mild bleeding disorder

Outcome Measures

Primary Outcomes (1)

  • bleeding and blood test results

    one year

Study Arms (1)

HEMOFIX

EXPERIMENTAL

3 grams a day

Dietary Supplement: HEMOFIX

Interventions

HEMOFIXDIETARY_SUPPLEMENT

unique complex herbal mixture

HEMOFIX

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteers and volunteers with a mild bleeding disorder

You may not qualify if:

  • people with thrombophilic and cardiovascular complications,
  • people who are treated with anti-coagulants,
  • women taking birth control pills
  • people with a history hypercoagulability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hadassah Medical Organization

Jerusalem, Israel

Location

MeSH Terms

Conditions

von Willebrand DiseasesMenorrhagia

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, InheritedBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesCoagulation Protein DisordersBlood Platelet DisordersHemorrhagic DisordersGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesUterine HemorrhageUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsMenstruation Disturbances

Study Officials

  • David Varon, Prof

    HMO

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2012

First Posted

July 27, 2012

Study Start

September 1, 2016

Primary Completion

January 1, 2020

Study Completion

December 1, 2023

Last Updated

November 28, 2017

Record last verified: 2017-02

Locations

IL(1)